2 Blue-Chip Stocks Making Moves After Earnings

Aerospace giant Boeing (BA) reported stronger-than-expected second-quarter results, including narrower losses and its highest revenue in six years, yet the stock reversed initial gains to trade down 3.2% from an earlier 52-week high. Concurrently, UnitedHealth Group (UNH) missed Q2 earnings, revenue, and full-year forecasts due to higher medical costs, leading to a 4.5% decline that could mark a five-year closing low for the stock. Both Dow components experienced significantly elevated options trading volume following their respective announcements, reflecting heightened investor positioning.

Analysis

A significant divergence in performance and outlook is evident between Dow components Boeing (BA) and UnitedHealth Group (UNH) following their second-quarter earnings reports. Boeing posted fundamentally strong results, including its highest revenue in six years at $22.75 billion and narrower-than-expected losses, which initially drove the stock to a 52-week high. However, the equity reversed course to trade down 3.2%, suggesting a 'sell-the-news' reaction or profit-taking on its 29.9% year-to-date gain, with the $228 level acting as immediate technical support. Conversely, UnitedHealth delivered a comprehensively negative report, missing analyst expectations on earnings, revenue, and its full-year forecast due to escalating medical costs. The market reacted swiftly, sending the stock down 4.5% towards a potential five-year closing low and exacerbating its 46.6% year-to-date decline. Both companies experienced a doubling of their average daily options volume, indicating significant investor repositioning and heightened expectations for volatility, with notable activity in near-term calls for BA and long-dated calls for UNH.

Key Decisions for Investors

• For Boeing, the contrast between strong operational performance and the negative stock reaction warrants a focus on the $228 technical support level; a hold above this price could present a buying opportunity, while a break below may signal further profit-taking.
• Given UnitedHealth's miss on all key metrics and its downwardly revised full-year forecast, investors should exercise extreme caution, as the drivers of underperformance appear systemic and the stock is exhibiting strong negative momentum.
• The surge in options activity for both stocks suggests continued volatility, and investors should consider the different theses implied by the trading: apparent short-term speculation in BA versus positioning for a potential, very long-term recovery in UNH.